Introduction
Prostate cancer is the most common cancer in men and a leading cause of male cancer mortality in Western societies (1) . Androgen deprivation remains the mainstay of treatment for patients with advanced stage disease. However, the response to suppression of gonadal androgens is not durable and transition of metastatic disease to a lethal castration-resistant prostate cancer (CRPC) is inevitable. It is now widely recognized that CRPC progression results from many different alterations of the androgen/AR axis that promote continued androgen receptor (AR) transcriptional activity. Novel androgen biosynthesis inhibitors (e.g. abiraterone acetate) and AR antagonists (e.g. These variants typically contain exons 1-3, but lack portions of the carboxyterminal LBD, and may be constitutively active (5, 6) . AR-Vs have been shown to drive androgen-independent cell proliferation in a manner that is resistant to antiandrogens, including enzalutamide (7) . The expression of ARVs is higher in CRPC compared to primary hormone-naïve prostate cancer and is reported to be mostly lacking in normal prostate epithelium (5, 6, (8) (9) (10) (11) .
Constitutively active AR-Vs have been implicated as a mechanism of resistance to current hormonal therapies targeting the LBD (7, (12) (13) (14) (15) .
One of the best characterized variants, and the most frequently detected in 5 CRPC to date (11) , is the AR-V7 (also termed AR3), which contains exons 1-3 and 16 unique amino acids that arise from cryptic exon 3 (6) . AR-V7 localizes constitutively to the nucleus, and facilitates AR-FL nuclear localization in the absence of androgen (14) . AR-V7 upregulation mitigates the ability of the AR antagonist enzalutamide to inhibit AR-FL nuclear trafficking (14) . AR-V7 may also direct a distinct transcriptional program to AR-FL, including the transcription of several cell-cycle-related genes in addition to canonical androgen-responsive genes (11, 16) . Recent clinical studies have linked AR-V7 expression in circulating tumor cells (CTC) and CRPC tissue with resistance to enzalutamide and abiraterone (17, 18) . This highlights an urgent need for alternative treatment strategies targeting AR-Vs.
HSP90 is a molecular chaperone essential for the late stage maturation, stability and function of a large number of client proteins involved in key signal transduction pathways in prostate cancer, including AR, AKT and the glucocorticoid receptor (GR) (19) (20) (21) . A key requirement for the transcriptional activity of steroid receptors is the interaction of unbound receptor with the HSP90 chaperone machinery. This interaction occurs exclusively through the LBD via direct binding to HSP40 and HSP70 (22, 23) . In prostate cancer cells inhibition of HSP90 chaperone activity impairs the nuclear translocation of AR-FL and enhances the degradation of AR-FL protein resulting in decreased AR-FL transcriptional output (20, 24, 25) and prostate cancer cell proliferation (26, 27) . Conversely, recent studies have suggested that AR-V7 nuclear translocation and transcriptional activity does not require HSP90 activity (28, 29) although HSP90 has been proposed as a therapeutic target in CRPC.
Several HSP90 inhibitors are undergoing clinical trial (29, 30) . In this study, we investigated the effect of HSP90 inhibition in prostate cancer cells expressing AR-V7. We demonstrate that HSP90 inhibition reduces expression of AR-V7. Interestingly, we show that AR-V7 down-regulation is not due to a traditional client-chaperone mechanism but results from disruption of AR splicing following HSP90 inhibition. 
Methods

Cell growth inhibition
Cell growth inhibition was assessed using the sulforhodamine B assay (SRB) (32) . The GI 50 was calculated as the drug concentration that inhibits cell growth by 50% compared with control growth using GraphPad Prism software.
Cell-cycle analysis
Cell cycle distribution and sub-G1 populations were analyzed by flow cytometry using propidium iodide staining (33) . Data were analysed with the Flowjo Software. 
Cell lysis and Western blot analysis
Co-immunoprecipitation
Whole cell lysates were obtained using Pierce IP Lysis buffer (Thermo ) were plated on 6-well plates and reverse transfected using the X-tremeGENE HP DNA Transfection Reagent (3 µl per well; Roche) (34) .
The plasmid constructs (1 µg DNA per well) used were pcDNA3.1-AR-V7
(encoding the V7 truncated AR isoform, a gift from Dr Jun Luo, Johns Hopkins University, Baltimore, USA), and F527-AR (encoding the full-length AR) (34) .
Tumor xenograft studies
Subcutaneous 22Rv1 solid tumor xenografts were prepared by serial passaging in male NMRI nu/nu mice (Harlan). Tumors were measured twice weekly with micro-calipers and tumor volumes determined using the formula:
(length 
Immunohistochemistry
Immunohistochemistry (IHC) for AR N-terminus domain (AR-NTD), HSP72,
Ki67 and cleaved caspase 3 was performed on 4 µm FFPE tumor sections.
Details of the IHC assays are provided in Supplementary Table 3 . Slides were counterstained with hematoxylin (TCS Biosciences Ltd), dehydrated, and mounted with DPX mountant (Sigma). All sections were scored by a pathologist blinded to treatment information.
RNA-Sequencing (RNA-Seq)
Total cellular RNA was extracted and purified using the RNeasy Mini Kit (Qiagen). RNA integrity was determined by Bioanalyzer 2100 (Agilent Technologies) and only samples with a RNA Integrity Numbers ≥9.5 were used. 500 ng of RNA was prepared into a library using the TruSeq RNA sample prep kit v2 (Illumina), and then clustered and sequenced on a Hi-Seq 
Statistical analyses
Effects of different treatments were compared using the Student's t test, Mann-Whitney test or ANOVA. Survival analysis was performed by KaplanMeier methods and log-rank analysis using quadruplication of the tumor as surrogate endpoint. In the RNA-seq analysis, the supportive reads of each alternative splicing event were counted, with the inclusion level being estimated using a Bayesian model as described by Shen et al., 2012 (36) .
Pairwise comparisons of each splicing event were performed among treatments using the Markov chain Monte Carlo method coupled with a simulation-based adaptive sampling procedure to calculate the p-value (36).
Sample replicates were used to control variability within-treatment groups.
The false discovery rate (FDR) was obtained by the Benjamini-Hochberg method with a FDR <0.05 being employed for the differential alternative splicing significance assessment.
Results
HSP90 targeting inhibits proliferation of prostate cancer cells expressing AR-V7
We initially examined the effects of the first-generation HSP90 inhibitors tanespimycin (17-AAG) and alvespimycin (17-DMAG) and the second- VCaP, and also the growth of the androgen-independent 22Rv1 and LNCaP95 cell lines, which are resistant to the AR antagonist enzalutamide (7, 11) ( Table 1) . Our results confirmed previous observations that AR-V7 expression does not confer resistance to HSP90 inhibitors in prostate cancer cells (29) .
HSP90 targeting depletes AR-FL and AR-V7 in prostate cancer cell lines
We then investigated the effect of HSP90 inhibition on AR-FL and AR-V7
protein levels in prostate cancer cells expressing both the AR-FL and AR-V7. These results confirmed AR-FL depletion following HSP90 inhibition and also indicated for the first time that AR-V7 protein level is also decreased when HSP90 is inhibited.
AR-V7 protein is more stable than AR-FL and is not directly affected by
HSP90 inhibition
HSP90 inhibition results in protein client destabilization and degradation by the ubiquitin-proteasome pathway (39) . Ubiquitinated proteins first accumulate in the cytosol and become aggregated and relocated in the detergentinsoluble fraction of cells when proteasomes are inhibited. To evaluate whether AR-V7 protein depletion was due to increased proteasomal degradation after HSP90 blockade, we examined the impact of the proteasome inhibitor MG132 on AR-V7 depletion by onalespib. VCaP cells were treated with onalespib in the presence or absence of proteasome inhibitor MG132 for 24 hours. As expected, addition of MG132 to onalespib treatment induced accumulation of high-molecular weight ubiquitinated AR-FL forms that were redistributed to the detergent-insoluble fraction (Figure 2A ).
Such accumulation of high-molecular weight AR-V7 forms was not observed, suggesting the lack of involvement of the proteasomal pathway in AR-V7 depletion by onalespib (Figure 2A) .
To determine whether the observed decrease in AR-V7 protein in onalespib- 
AR-V7 bypasses direct HSP90 binding
A key requirement for steroid receptor activity is the interaction of unliganded receptors with the HSP90 chaperone machinery (40) . To further examine the relationship between AR-V7 and HSP90, we determined by coimmunoprecipitation assays whether AR-V7 and HSP90 protein complexes exist in prostate cancer cells that endogenously express the variant ( Figure   2D ). As expected, AR-FL formed a complex with HSP90 when the cells were cultured in androgen-depleted media (Figure 2D top panel) . In contrast, AR-V7 did not co-immunoprecipitate detectable amounts of HSP90 ( Figure 2D 
bottom panel). This was in agreement with results of Gills et al. in PC3 cells
exogenously expressing the AR-V7 (29) . Also, in keeping with a previous report (7), using subcellular fractionation we confirmed that AR-V7 entered the nucleus independently of HSP90 activity (data not shown). Taken together, these results indicated that AR-V7 protein, unlike AR-FL, does not require HSP90 chaperone.
HSP90 inhibition induces AR-V7 mRNA downregulation
To evaluate whether AR-V7 depletion was due to down-regulation of AR mRNA expression we next examined levels of AR transcripts following onalespib treatment ( Figure 3A) . In VCaP, 22Rv1 and LNCaP95 cells treated Table 5 ).
Onalespib exhibits antitumor activity against AR-V7-expressing 22Rv1 tumor xenografts
We next evaluated the effect of onalespib on tumor growth and AR-V7 levels in 22Rv1 subcutaneous solid tumor xenografts. Onalespib was administered intraperitoneally at 70 mg/kg in a twice a week schedule (35) . Onalespib reduced tumor growth significantly when administered twice a week (P < 0.001 against the vehicle control; Figure 5A ) and significantly prolonged survival (
Figure 5B In conclusion, our observations confirm that AR-V7 protein functions independently of HSP90, and that AR-V7 is not a direct HSP90 client (29) .
However, we have demonstrated for the first time that HSP90 inhibition leads to the depletion of AR-V7 protein by downregulating AR-V7 mRNA splicing. 
